CTCs Demonstrate Predictive Power in Prostate Cancer

Tony Hagen @oncobiz
Published: Wednesday, Feb 21, 2018
Howard I. Scher, MD

Howard I. Scher, MD
Investigators looking for a superior means of testing for response to therapy in metastatic castration-resistant prostate cancer (mCRPC) said they found the solution in a study of circulating tumor cells (CTCs). These markers proved to be better, earlier predictors of response than prostate-specific antigen (PSA) tests.


Figure. CTC Measures Prove Better Determinants of Response1

“To develop new therapeutic agents requires the ability to determine whether a systemic therapy has clinical benefit (eg, improving how a patient feels and functions and how long the patient survives),” corresponding author Howard I. Scher, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center in New York, New York, and coauthors wrote.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication